Hutson, Thomas E.

Abiraterone and Increased Survival in Metastatic Prostate Cancer

de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 4,407

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 3,019

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine

Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management

Cited by 2,156

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

McDermott, D. F., Huseni, M. A., Atkins, M. B., Motzer, R. J., Rini, B. I., Escudier, B., Fong, L., Joseph, R. W., Pal, S. K., Reeves, J. A., et al. (2018) · Nature Medicine

Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers

Cited by 1,260